U.S. markets closed

REGENXBIO Inc. (RGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
28.86+0.36 (+1.26%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close28.50
Open28.82
Bid28.76 x 900
Ask29.00 x 900
Day's Range27.83 - 28.96
52 Week Range20.03 - 54.97
Volume177,599
Avg. Volume346,183
Market Cap1.119B
Beta (5Y Monthly)0.94
PE Ratio (TTM)N/A
EPS (TTM)-3.64
Earnings DateNov 03, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est61.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Do Hedge Funds Love Regenxbio Inc (RGNX)?
    Insider Monkey

    Do Hedge Funds Love Regenxbio Inc (RGNX)?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

  • REGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)
    PR Newswire

    REGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)

    REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the expansion of the RGX-121 program for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome, to gain additional insight into the neurodegenerative manifestations of the disease and evaluate RGX-121 in a broader patient population. RGX-121 is an investigational one-time gene therapy, designed to use the AAV9 vector to deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme directly to the central nervous system (CNS) through intracisternal administration.

  • REGENXBIO to Participate in Upcoming Investor Conferences
    PR Newswire

    REGENXBIO to Participate in Upcoming Investor Conferences

    REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it will participate in the following upcoming investor conferences, which will each be held in a virtual meeting format: